Status:
COMPLETED
Red Cell Distribution Width Versus Presepsin (Soluble CD14) as a Prognostic Marker in Critically-ill Sepsis Patients
Lead Sponsor:
Ain Shams University
Conditions:
Sepsis
Eligibility:
All Genders
18-65 years
Brief Summary
Presepsin (soluble CD14 subtype) is a novel marker with growing body of evidence supporting its accuracy and value for the diagnosis of sepsis. Patients with sepsis showed higher Prsepsin levels compa...
Eligibility Criteria
Inclusion
- Male or female aged 18 65 years.
- Appropriate clinical data to enable classification into sepsis or SIRS according to Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).
- Written informed consent by the patient or guardian
Exclusion
- No informed consent
- Renal failure
- Liver failure
- Hematologic diseases
- Neutropenia
- Malignancy
- Chemotherapy during the previous 90 days.
- Patients using antibiotics at presentation
Key Trial Info
Start Date :
August 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 24 2018
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT03796715
Start Date
August 1 2018
End Date
December 24 2018
Last Update
January 8 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ain Shams University Hospitals
Cairo, Egypt, 11591